Advertisement

Topics

Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects

2014-10-03 16:35:29 | BioPortfolio

Published on BioPortfolio: 2014-10-03T16:35:29-0400

Clinical Trials [952 Associated Clinical Trials listed on BioPortfolio]

Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05

This study will evaluate longitudinal change of tau deposition as measured by 18F-AV-1451 uptake over time.

18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

This study will explore the use of 18F-AV-1451 as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.

18F-AV-1451 Autopsy Study

This study is designed to test the relationship between ante-mortem 18F-AV-1451 Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's dis...

Clinical Evaluation of 18F-AV-1451

This study is designed to expand the database of 18F-AV-1451 safety and tau binding as measured by PET imaging and to provide standardized conditions for 18F-AV-1451 use, data collection a...

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol)...

PubMed Articles [14957 Associated PubMed Articles listed on BioPortfolio]

Scan-time Corrections for 80-100 Minute Standardized Uptake Volume Ratios to Measure the 18F-AV-1451 Tracer for Tau Imaging.

The 18F-AV-1451 PET tracer binds to tau, an Alzheimer's Disease (AD) biomarker. The standardized uptake value ratio (SUVR) 80-100 min window is widely used to quantify tau binding, although 18F-AV-145...

Longitudinal and cross-sectional structural magnetic resonance imaging correlates of AV-1451 uptake.

We examined the relationship between in vivo estimates of tau deposition as measured byF-AV-1451 tau positron emission tomography imaging and cross-sectional cortical thickness, as well as rates of a...

Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.

Neuroimaging modalities can measure different aspects of the disease process in Alzheimer's disease, although the relationship between these modalities is unclear.

Quantitative evaluation of tau PET tracers F-THK5351 and F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization.

Off-target binding in the reference region is a challenge for recent tau tracers F-AV-1451 and F-THK5351. The conventional standardized uptake value ratio (SUVR) method relies on the average uptake fr...

A systems-based model of Alzheimer's disease.

The new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease has been developed to accelerate drug discovery and offer a common structure and language...

Medical and Biotech [MESH] Definitions

The period of history from 1451 through 1600 of the common era.

Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.

Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.

A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)

A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.

More From BioPortfolio on "Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial